1. What's New From ERA-EDTA 2018?

3. Treatment Gaps in CKD

4. Progression of Kidney Disease Renocardiac Syndrome

5. Bardoxolone Phase 2 and 3 Studies in Patients With Diabetic CKD

6. BEACON Sustained Increase in eGFR

7. Exclusion of At-Risk Patients in BEACON Appears to Improve Risk-Benefit Profile of Bardoxolone

8. TSUBAKI Study (Japan) in Patients With Diabetic CKD

9. LARIAT Study Phase 2 Trial Assessing Bardoxolone in PAH

10. Alport Syndrome

11. CARDINAL Study Phase 2 Study in Patients With Alport Syndrome

12. PHOENIX Study Design

13. PHOENIX Study Initial Results From a Phase 2 Trial in Patients With ADPKD and IgA Nephropathy

14. Delaying Progression of Kidney Disease

15. Increases in Urinary Protein Are Consistent With Increases in GFR and Not Injury

16. Kidney Failure Outcomes

17. Retained Benefit After Drug Discontinuation Insights From the REPRISE Trial in ADPKD

18. CARDINAL Phase 3 Study Design

19. Long-Term Impact of Bardoxolone on Kidney?

20. Future Considerations for Managing Patients With CKD

21. Other Possible Agents Targeting Inflammation

22. Final Thoughts

23. Abbreviations

24. Abbreviations (cont)